Radioiodinated metaiodobenzylguanidine : a review of its biodistribution and pharmacokinetics, drug interactions, cytotoxicity and dosimetry

Since the introduction of radioiodinated metaiodobenzylguanidine in 1980, considerable research has been performed, both in the chemical field and in medical sciences. However, despite the wide use of radioiodinated metaiodobenzylguanidine, knowledge about its pharmacology is still limited. This pap...

Full description

Saved in:
Bibliographic Details
Published in:European Journal of Nuclear Medicine 1994-06, Vol.21 (6), p.545-559
Main Authors: WAFELMAN, A. R, HOEFNAGEL, C. A, MAES, R. A. A, BEIJNEN, J. H
Format: Article
Language:English
Subjects:
3-Iodobenzylguanidine
Animals
Antineoplastic Agents
Biological and medical sciences
Contrast Media
Contrast media. Radiopharmaceuticals
Drug Interactions
Humans
Iodine Radioisotopes
Iodobenzenes - pharmacokinetics
Iodobenzenes - pharmacology
Iodobenzenes - therapeutic use
Medical sciences
Pharmacology. Drug treatments
Tissue Distribution
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Since the introduction of radioiodinated metaiodobenzylguanidine in 1980, considerable research has been performed, both in the chemical field and in medical sciences. However, despite the wide use of radioiodinated metaiodobenzylguanidine, knowledge about its pharmacology is still limited. This paper reviews the biodistribution and pharmacokinetics, drug interactions, cytotoxicity and dosimetry of radioiodinated metaiodobenzylguanidine. Iodine-131 metaiodobenzylguanidine therapy is in general well tolerated, but its effectiveness needs improvement. Also whole-body dosimetry as part of treatment planning needs to be improved. Future prospects on these items are included in this review.
ISSN:0340-6997
1619-7089
DOI:10.1007/BF00173043